Search results | solid tumors

Reports

Solid Tumor Partnering

The Solid Tumor Partnering provides understanding and access to the solid tumor partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Amgen partners with Micromet for BiTE antibodies for solid tumors

The collaboration agreement between Amgen Micromet is for the research of BiTE antibodies against three undisclosed solid tumor targets

Pharmacyclics: Partnering activity 2009-2014

Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline.

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Seattle Genetics : Biotech industry partnering activity 2009-2014

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment.

Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Oncology partnering – recent deals analysis 2009-2014

Partnering in the last decade has seen an increase in oncology partnering with an increase in modern diagnostic technologies, according to recent partnering deals analysis

Onyx Pharmaceuticals: M&A activity 2009-2014

Onyx Pharmaceuticals purchased Proteolix in October 2009 for a deal valued at $851 million. Proteolix was a privately owned biopharmaceutical company focussed in hematological malignancies and solid tumors.

Onyx Pharmaceuticals: Partnering activity 2009-2014

Onyx Pharmaceuticals is a subsidiary of Amgen, based in San Francisco, California.

Diagnostics

Diagnostics are any kind of medical test performed to aid in the diagnosis or detection of disease.

Therapeutic partnering

Partnering with a therapeutic end point in mind.

Events

Sorry, your search returned no results.


Deals

Merck and Tetralogic in solid tumor clinical pact

TetraLogic and Merck will collaborate on a Phase 1 study

Eisai and Merck in solid tumour triple therapy pact

Eisai and Merck announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab

Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets

Collaboration agreement with Amgen for the research of BiTE antibodies against three undisclosed solid tumor targets

Bayer Schering Pharma exercises option to develop solid tumor BiTE antibody with Micromet

Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

Mirna Therapeutics secures $41.8mn series D

Mirna Therapeutics announced the completion of a $41.8 million Series D financing

AstraZeneca and Innate Pharma in IPH2201 deal

Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca

Ventana and Astellas in automated tissue diagnostics pact

Ventana Medical Systems has entered into master collaboration agreement with Astellas Pharma to develop novel automated tissue diagnostics

Eisai returns EZH2 program, including EPZ-6438 to Epizyme

Epizyme has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai

Kura Oncology licenses tipifarnib; banks $60 million financing

Kura Oncology has entered into an agreement with Janssen Pharmaceutica for an exclusive license to develop and commercialize tipifarnib in the field of oncology

Celgene licenses AG-120 from Agios

Agios Pharmaceuticals announced that its collaboration partner Celgene has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120